FSN Ref: R2021-02



Date: April 6th, 2021

Rev 1: April 6th, 2021

Urgent Field Safety Notice

Cemento Mini Set for Cemento-MP

For Attention of:

Physicians, users, and OR staff in the field of spine surgery

Contact details of local representative (name, e-mail, telephone, address etc.) Macromed (UK) Ltd 4 Petre Road, Clayton Business Park, Clayton Le Moors, Accrington, Lancs BB5 5JB United Kingdom T: 0845 0345 160 F: 0845 0345 161 Email: admin@macromed.co.uk



Fig. 1: Optimed Cemento Mini Set for Cemento-MP

Rev 1: April 6th, 2021

FSN Ref: R2021-02



Urgent Field Safety Notice (FSN) Cemento Mini Set for Cemento-MP

		1. Information on Affected Devices*		
1.	1. Device Type(s)			
	Cemento Mini Set for Cemento-MP: complementary set with injection cylinder,			
	connection hose, aspiration cannula, and Luer Lock adapter (see fig. 1 above)			
1. 2. Commercial name(s)				
	Cemer	nto Mini Set for Cemento-MP		
1.	3.	Unique Device Identifier(s) (UDI-DI)		
	n/a			
1.	4.	Primary clinical purpose of device(s)		
	The op	timed Cemento MP is an injection system for cemetoplasty / vertebroplasty.		
1.	1. 5. Device Model/Catalogue/part number(s)			
	1382-0	100		
1.	6.	Software version		
	n/a			
1.	7.	Affected serial or lot number range		
	13622	13661, 13712, 13822		
1.	8.	Associated devices		
	n/a			

	2 Reason for Field Safety Corrective Action (FSCA)		
2	1. Description of the product problem		
~	In recent weeks, in very rare cases, an unexpected leakage of the cement mixture		
-	occurred at the distal luer lock of the connection hose (see fig. 2)		
2	2. Hazard giving rise to the FSCA		
-	We have been informed about 4 cases with cement leakage; none of the patients has been harmed. The user can clearly see the leakage of the cement because it happens outside the patient. When the user notices a leakage, he must use a new set. Since the cement cannot be applied into the patient in case of a leakage, there is no risk to the patient. We decided to recall the affected products, because the malfunction is not		
	acceptable, even if there is no risk for the patients.		
2	3. Probability of problem arising		
	There are four lots which may be affected by this leakage. 697 mini sets of these four lots has been delivered by optimed, and four cases of leakage has been reported. The complaint rate is 0.57%.		
2	4. Predicted risk to patient/users		
	According to the available information, there is no risk for patients.		
2	5. Further information to help characterise the problem		
	n/a		
2	6. Background on Issue		
	The root cause was identified as a deviation in the tolerance during production of the		
	rotatable Luer lock connection. Only products of the 4 above-mentioned lots can be affected by this manufacturing defect. Other lots are not affected by this possible defect.		
2	7. Other information relevant to FSCA		
	Other lots of this part number and other products are not affected.		

Rev 1: April 6th, 2021

FSN Ref: R2021-02






Fig. 2: Leakage at distal Luer Lock of the connection hose

		3.	. Type of Action	to mitigate	the risk
3.	1.	Action To Be Taker	n by the User		
		\boxtimes Identify Device \boxtimes C	Quarantine Device	⊠ Return Devi	ce
		On-site device modific	ation/inspection		
		□ Follow patient management recommendations			
		\Box Take note of amendment/reinforcement of Instructions For Use (IFU)			
		□ Other □ N	None		
		The affected products should return all products of the affe	•	ents. Quarantine all	affected products and
3.	2.	By when should the action be completed?	As soon	n as possible	
3.	3.	Particular consideration	ns for: n/a C	hoose an item.	
		Is follow-up of patients	or review of patients' p	previous results	recommended?
		No			
3.	4. (If y	Is customer Reply Req yes, form attached spec		rn)	Yes

Rev 1: April 6th, 2021





3.	5.	5. Action Being Taken by the Manufacturer		
			 On-site device modification/inspective IFU or labelling change None 	ection
		All affected products are separated at optimed and will be exchanged.		
3	6.	By when should the action be completed?	As soon as possible	
3.	7.	Is the FSN required to be communicated to the patient No /lay user?		
3	8.	If yes, has manufacturer provided additional information suitable for the patient/lay user in a patient/lay or non-professional user information letter/sheet?		
		n/a Choose an item.	Choose an item.	



FSN Ref: R2021-02



	4.	General Information	
4.	1. FSN Type	New	
4.	 For updated FSN, reference number and date of previous FSN 	n/a	
4.	3. For Updated FSN, key new information	ation as follows:	
	n/a		
4.	 Further advice or information already expected in follow-up FSN? 	No	
4	5. If follow-up FSN expected, what is the further advice expected to relate to:		
4	n/a		
4	 Anticipated timescale for follow- up FSN 	n/a	
4.	7. Manufacturer information (For contact details of local representative refer to page 1 of this FSN)		
	a. Company Name Optimed Medizinische Instrumente GmbH		
	b. Address	Ferdinand-Porsche-Str. 11, 76275 Ettlingen, Germany	
	c. Website address www.optimed.com		
4.	8. The Competent (Regulatory) Author communication to customers.	prity of your country has been informed about this	
4.	9. List of attachments/appendices:	n/a	
4.	10. Name/Signature	Dr. Ernst Nennig, PhD Health and Safety Officer for Medical Devices	
		06.04.2021 S. Mai	

Transmission of this Field Safety Notice
This notice needs to be passed on all those who need to be aware within your organisation or to any organisation where the potentially affected devices have been transferred. (As appropriate)
Please transfer this notice to other organisations on which this action has an impact. (As appropriate)
Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.
Please report all device-related incidents to the manufacturer, distributor or local representative, and the national Competent Authority if appropriate, as this provides important feedback.